Malaysian Journal of Fundamental and Applied Sciences,
Год журнала:
2024,
Номер
20(6), С. 1440 - 1459
Опубликована: Дек. 16, 2024
Glucose-6-phosphate
dehydrogenase
deficiency
(G6PDD)
is
a
major
enzymatic
disease
affecting
human
red
blood
cells
(RBCs),
causing
hemolytic
anemia
due
to
the
diminish
of
nicotinamide
adenine
dinucleotide
phosphate
hydrogen
(NADPH)
synthesis
and
altered
redox
balance
within
erythrocytes.
This
study
sought
correct
defect
in
G6PDChatham
(Ala355Thr)
caused
by
loss
interactions
(hydrogen
bonds
salt
bridges)
docking
AG1
molecule
at
dimer
interface,
thus
restoring
these
lost
interactions.
The
enzyme
conformation
was
then
analyzed
before
after
binding
using
molecular
dynamics
simulation
(MDS).
reasons
behind
severity
acute
(AHA)
were
explained
several
parameters,
such
as
root-mean-square
deviation
(RMSD),
fluctuation
(RMSF),
bonds,
bridges,
radius
gyration
(Rg),
solvent
accessible
surface
area
(SASA),
covariance
matrix
analysis.
Structural
alterations
G6PDChatham,
including
absence
key
region
variant
structure,
can
significantly
impact
protein
stability
function,
subsequently
contributing
severity.
Upon
binding,
missing
resorted
structural
variant.
restoration
improves
restores
G6PD
function.
To
develop
new
activators,
analogues
(SY7,
SY8,
SY9,
SY10)
rationally
developed
substituting
linker
structure
with
other
functional
groups
Avogadro
software.
These
compounds
successfully
synthesized
docked
where
best
affinity
ranged
between
-8.0
-9.1
kcal/mol.
promising
activator,
predicted
be
easily
metabolized
excreted,
making
it
less
likely
cause
toxicity.
Its
high
drug
score,
drug-likeness,
favorable
safety
profile
make
strong
candidate
for
cellular
testing.
toxicity
risk
assessment
supported
overall
increasing
confidence
finding
additional
small-molecule
activators
G6PDD
disorder.
Amidst
effective
treatments,
discovery
hopes
improve
lives
those
AHA
assisting
development
appropriate
pharmaceuticals
G6PDD.
Chemistry & Biodiversity,
Год журнала:
2024,
Номер
21(12)
Опубликована: Авг. 22, 2024
Abstract
Structural
modification
is
an
effective
way
to
improve
the
antifungal
activity
of
natural
products
and
has
been
widely
used
in
development
novel
fungicides.
In
this
work,
a
series
aminocoumarin‐based
Schiff
bases
were
synthesized
characterized
by
1
H‐NMR,
13
C
NMR
HR‐MS
spectra.
The
vitro
inhibition
all
compounds
was
tested
against
four
phytopathogenic
fungi
(
Alternaria
solani
,
Fusarium
oxysporum
Botrytis
cinerea
alternata
)
using
mycelial
growth
rate
method.
results
showed
that
most
target
exhibited
significant
activities.
particular,
5b
5c
5d
5h
5n
7c
7n
7p
more
than
commercially
available
fungicides,
chlorothalonil
azoxystrobin.
structure‐activity
relationship
revealed
electron‐withdrawing
groups
with
electronegativity
introduced
at
C‐3
position
improving
inhibitory
halogenated
benzaldehydes
would
be
necessary
preparation
bases.
compound
(EC
50
=8.73
μg/mL)
=26.25
much
better
positive
controls
(chlorothalonil
azoxystrobin).
Therefore,
could
serve
as
promising
lead
for
broad‐spectrum
which
useful
applications
agriculture.
ACS Applied Polymer Materials,
Год журнала:
2024,
Номер
6(17), С. 10263 - 10273
Опубликована: Авг. 21, 2024
Compared
with
traditional
liquid
electrolytes,
solid
polymer
electrolytes
have
good
formability,
lightweight,
and
safety;
especially,
poly(ethylene
oxide)
(PEO)-based
strong
dissociation
capability
alkali
salts.
However,
linear
PEO-based
polymers
are
easy
to
crystallize.
The
crystal
domains
of
the
will
greatly
hinder
transportation
ions.
In
this
study,
A2
B3
monomers
were
first
synthesized
by
click
chemistry.
Then,
a
series
hyperbranched
polyelectrolytes
(HBPEs)
esterification
using
an
+
monomer.
Finally,
certain
amount
HBPEs
was
mixed
poly(amic
acid)
solution
prepare
HBPE
composite
membranes.
It
is
found
that
PI-HBPE30-G3
membrane
has
superior
thermal
stability,
mechanical
properties,
high
ionic
conductivity
at
80
°C.
Moreover,
exhibits
electrochemical
performance.
fabricated
LiFePO4|PI-HBPE30-G3|Li
cell
shows
excellent
cycling
discharge
capacity
maintained
137
mA
h
g–1
0.2C
after
200
cycles,
Coulombic
efficiency
virtually
invariant
above
99%
room
temperature.
This
paper
highlights
electrolyte
can
be
used
in
next-generation
safe
power
devices.
Malaysian Journal of Fundamental and Applied Sciences,
Год журнала:
2024,
Номер
20(6), С. 1440 - 1459
Опубликована: Дек. 16, 2024
Glucose-6-phosphate
dehydrogenase
deficiency
(G6PDD)
is
a
major
enzymatic
disease
affecting
human
red
blood
cells
(RBCs),
causing
hemolytic
anemia
due
to
the
diminish
of
nicotinamide
adenine
dinucleotide
phosphate
hydrogen
(NADPH)
synthesis
and
altered
redox
balance
within
erythrocytes.
This
study
sought
correct
defect
in
G6PDChatham
(Ala355Thr)
caused
by
loss
interactions
(hydrogen
bonds
salt
bridges)
docking
AG1
molecule
at
dimer
interface,
thus
restoring
these
lost
interactions.
The
enzyme
conformation
was
then
analyzed
before
after
binding
using
molecular
dynamics
simulation
(MDS).
reasons
behind
severity
acute
(AHA)
were
explained
several
parameters,
such
as
root-mean-square
deviation
(RMSD),
fluctuation
(RMSF),
bonds,
bridges,
radius
gyration
(Rg),
solvent
accessible
surface
area
(SASA),
covariance
matrix
analysis.
Structural
alterations
G6PDChatham,
including
absence
key
region
variant
structure,
can
significantly
impact
protein
stability
function,
subsequently
contributing
severity.
Upon
binding,
missing
resorted
structural
variant.
restoration
improves
restores
G6PD
function.
To
develop
new
activators,
analogues
(SY7,
SY8,
SY9,
SY10)
rationally
developed
substituting
linker
structure
with
other
functional
groups
Avogadro
software.
These
compounds
successfully
synthesized
docked
where
best
affinity
ranged
between
-8.0
-9.1
kcal/mol.
promising
activator,
predicted
be
easily
metabolized
excreted,
making
it
less
likely
cause
toxicity.
Its
high
drug
score,
drug-likeness,
favorable
safety
profile
make
strong
candidate
for
cellular
testing.
toxicity
risk
assessment
supported
overall
increasing
confidence
finding
additional
small-molecule
activators
G6PDD
disorder.
Amidst
effective
treatments,
discovery
hopes
improve
lives
those
AHA
assisting
development
appropriate
pharmaceuticals
G6PDD.